This review is an update of the comprehensive review by Gendarme et al. [4], with a specific focus on the rapidly evolving therapeutic landscape of ROS1-positive non-small cell lung cancer (NSCLC). The gene discussed is ROS1; the disease is non-small cell lung carcinoma.